Literature DB >> 23034387

Physiology of the orexinergic/hypocretinergic system: a revisit in 2012.

Jyrki P Kukkonen1.   

Abstract

The neuropeptides orexins and their G protein-coupled receptors, OX(1) and OX(2), were discovered in 1998, and since then, their role has been investigated in many functions mediated by the central nervous system, including sleep and wakefulness, appetite/metabolism, stress response, reward/addiction, and analgesia. Orexins also have peripheral actions of less clear physiological significance still. Cellular responses to the orexin receptor activity are highly diverse. The receptors couple to at least three families of heterotrimeric G proteins and other proteins that ultimately regulate entities such as phospholipases and kinases, which impact on neuronal excitation, synaptic plasticity, and cell death. This article is a 10-year update of my previous review on the physiology of the orexinergic/hypocretinergic system. I seek to provide a comprehensive update of orexin physiology that spans from the molecular players in orexin receptor signaling to the systemic responses yet emphasizing the cellular physiological aspects of this system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23034387     DOI: 10.1152/ajpcell.00227.2012

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  48 in total

1.  Orexin/hypocretin receptor signalling: a functional perspective.

Authors:  C S Leonard; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

3.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

Review 4.  Functional Changes of Orexinergic Reaction to Psychoactive Substances.

Authors:  Vincenzo Monda; Monica Salerno; Francesco Sessa; Renato Bernardini; Anna Valenzano; Gabriella Marsala; Christian Zammit; Roberto Avola; Marco Carotenuto; Giovanni Messina; Antonietta Messina
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

5.  Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery.

Authors:  Jaana Putula; Tero Pihlajamaa; Jyrki P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-11-05       Impact factor: 8.739

6.  BAT is independently affected by peripheral and central pathways.

Authors:  J P Kukkonen
Journal:  Int J Obes (Lond)       Date:  2018-03       Impact factor: 5.095

7.  Orexin/hypocretin activates mTOR complex 1 (mTORC1) via an Erk/Akt-independent and calcium-stimulated lysosome v-ATPase pathway.

Authors:  Zhiqiang Wang; Shimeng Liu; Miyo Kakizaki; Yuuki Hirose; Yukiko Ishikawa; Hiromasa Funato; Masashi Yanagisawa; Yonghao Yu; Qinghua Liu
Journal:  J Biol Chem       Date:  2014-10-02       Impact factor: 5.157

8.  The Neuropeptide Orexin-A Inhibits the GABAA Receptor by PKC and Ca2+/CaMKII-Dependent Phosphorylation of Its β1 Subunit.

Authors:  Divya Sachidanandan; Haritha P Reddy; Anitha Mani; Geoffrey J Hyde; Amal Kanti Bera
Journal:  J Mol Neurosci       Date:  2017-01-19       Impact factor: 3.444

Review 9.  Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster.

Authors:  Lisa J Wood; Kristianna Weymann
Journal:  Curr Opin Support Palliat Care       Date:  2013-03       Impact factor: 2.302

10.  Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats.

Authors:  Aihua Li; Charles C T Hindmarch; Eugene E Nattie; Julian F R Paton
Journal:  J Physiol       Date:  2013-05-13       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.